Open AccessA multi‐biomarker follow‐up study of patients with multiple sclerosis
Author(s) -
Stilund Morten,
Gjelstrup Mikkel Carstensen,
Christensen Tove,
Møller Holger Jon,
Petersen Thor
Publication year - 2016
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.509
Subject(s) - multiple sclerosis , clinically isolated syndrome , medicine , cerebrospinal fluid , biomarker , gastroenterology , osteopontin , disease , pathology , oncology , immunology , biochemistry , chemistry
Abstract Objectives This study aimed to examine the levels of the macrophage marker sCD 163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome ( CIS ) or relapsing‐remitting multiple sclerosis ( RRMS ), and assess relation to clinical indicators of prognosis, disease activity ( DA ), and changes in the levels of these biomarkers at follow‐up. Materials and Methods The clinical status and MRI were reevaluated in 56 patients more than 1 year after diagnosis with a median follow‐up time of 2 years. Levels of biomarkers in serum and cerebrospinal fluid ( CSF ) samples were evaluated by enzyme‐linked immunosorbent assays. Results There was no significant difference in time to DA between patients with CIS and RRMS . A high sCD 163 ratio (>0.07) was significantly ( P = 0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD 163 ratio levels decreased from 0.068 to 0.054 ( P = 0.026) in the CIS / RRMS ‐treated group. The CSF CXCL 13, CXCL 13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS / RRMS ‐treated group. Conclusions The levels of all biomarkers changed concurrently with MS treatment. The sCD 163 ratio was identified as a potential novel marker for time to DA .